2022美国替妥木单抗治疗甲状腺眼病的专家共识:解读与思考  

Interpretation and comments of 2022 American Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease

作　　者：黄文彬 何志伟 刘洲君 徐书杭[1] 刘超[1] Huang Wenbin;He Zhiwei;Liu Zhoujun;Xu Shuhang;Liu Chao(Department of Endocrinology,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Jiangsu Province Academy of Traditional Chinese Medicine,Key Laboratory of TCM Syndrome&Treatment of Yingbing of State Administration of Traditional Chinese Medicine,Nanjing 210028,China;Suzhou Wuzhong People′s Hospital,Suzhou 215128,China)

机构地区：[1]南京中医药大学附属中西医结合医院,江苏省中医药研究院内分泌科,国家中医药管理局瘿病证治重点研究室,南京210028 [2]苏州市吴中人民医院,苏州215128

出　　处：《国际内分泌代谢杂志》2024年第4期269-272,共4页International Journal of Endocrinology and Metabolism

基　　金：江苏省研究生实践创新计划项目(SJCX23_0819)。

摘　　要：甲状腺眼病(TED)是一种以眼球后及眶周组织浸润性病变为特征的一种自身免疫性疾病,严重影响患者的生活质量和身心健康,并增加个人、家庭和社会的经济负担。替妥木单抗(teprotumumab)因其独特的功效,成为唯一获美国食品药品监督管理局批准治疗TED的靶向生物制剂。2022年9月,由国际著名TED及眼整形专家Douglas教授牵头制定了第一部替妥木单抗治疗TED的专家共识,主要从药物适用范围、使用前患者评估、治疗方案、安全性、有效性以及随访监测等方面进行了阐述,为临床医师治疗TED提供了具体的指导与借鉴。Thyroid eye disease(TED)is an autoimmune disease characterized by infiltrative lesions of the retroocular and periorbital tissues,which can seriously affect the quality of life,physical and mental health,and increase the economic burden of families and society.Teprotumumab became the first drug approved by the Food and Drug Administration(FDA)to for the treatment of TED in 2020.In September 2022,Professor Douglas,an internationally renowned expert in TED and oculoplastic medicine,led the team and wrote the first expert consensus on the treatment of TED with teprotumumab.This consensus describes not only the indications and contraindications of teprotumumab therapy,but also patient evaluation,treatment plan,safety,follow-up monitoring,etc.,providing practical guidance and reference for clinicians.

关 键 词：替妥木单抗 甲状腺眼病 治疗 专家共识 

分 类 号：R771.3[医药卫生—眼科] R581[医药卫生—临床医学]